Pfizer, IncNYSE: PFE
Health Care · Pharmaceuticals
$25.28
-2.49%
Vol: 64.7M
Research Digest
Friday, June 19, 2026
Pfizer shares fell after disclosing the unexpected departure of CFO Dave Denton, who will step down on August 15.
On June 18, 2026, Pfizer disclosed that Chief Financial Officer Dave Denton will step down on August 15, with Cecile Guegan named interim CFO; shares fell roughly 2.7-3% on the news. Pfizer simultaneously reaffirmed its 2026 revenue guidance of $59.5 billion-$62.5 billion, signaling management's confidence despite the leadership change. The move matters because an unexpected CFO exit can unsettle investors during a period when Pfizer is repositioning toward obesity and oncology, with mid-stage programs including SOLIS-1 (obesity) and PF-08634404 (gastric cancer). The bear case is that the abrupt timing raises questions about internal stability and capital-allocation continuity, layered on top of looming patent cliffs and the company's reliance on pipeline and M&A to offset revenue erosion. Pfizer also recently settled VYNDAMAX patent litigation with generic makers, extending effective U.S. exclusivity to June 2031.
Previous Market Intelligence
13 daysJun 18Pfizer GLP-1 drug berobenatide posts 15.9% weight loss in Phase 2b, advancing to 10+ Phase 3 trials in 2026.Neutral▶
Pfizer presented Phase 2b data for berobenatide (PF-3944), its once-monthly GLP-1 receptor agonist, at the American Diabetes Association's 86th Scientific Sessions on June 6, 2026, showing 15.9% non-placebo-adjusted weight reduction at 32 weeks with no plateau. Analyst reactions were mixed — Guggenheim called the results "solid but undifferentiated" while BMO Capital called the tolerability profile "manageable." CEO Albert Bourla presented at Goldman Sachs Healthcare Conference on June 8, highlighting 20 pivotal studies planned for 2026 and four pending regulatory decisions. Shares fell roughly 1.3% on the ADA data day. A key near-term catalyst is the Be6A LUNG-01 overall survival readout expected mid-2026. The company reaffirmed 2026 guidance following strong Q1 results reported May 5.
Jun 17No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 16No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Michael Burry disclosed a new Pfizer stake, attracted to the dirt-cheap 6.66% dividend yield and 9x forward P/E.Mixed▶
Michael Burry's latest 13F disclosure included Pfizer as a new buy, drawn by the 6.66% dividend yield and roughly 9x forward P/E. Pfizer entered settlements with Dexcel Pharma, Hikma Pharmaceuticals and Cipla regarding Vyndamax patent infringement, extending the effective U.S. patent expiry to June 1, 2031. Pfizer continues to focus on oncology, where its drugs now represent roughly 27% of total revenue. The 2026 full-year guidance was reaffirmed at $2.80-$3.00 adjusted EPS and revenue of $59.5B-$62.5B. The stock trades around $25.75 with notable valuation gap vs. peers.
May 20Pfizer settled VYNDAMAX patent litigation with three generic drugmakers, extending effective US patent protection to June 2031.Mixed▶
Pfizer announced settlement agreements with Dexcel Pharma, Hikma Pharmaceuticals, and Cipla to resolve patent infringement lawsuits related to VYNDAMAX (tafamidis), pushing effective US patent expiry to June 1, 2031. As a result, VYNDAMAX revenues are now expected to stay relatively stable from 2028 through mid-2031, removing a near-term overhang on one of Pfizer's most important post-COVID growth drugs. Separately, Pfizer and Valneva reported their Lyme disease vaccine candidate showed 73.2% efficacy in the Phase 3 VALOR trial, with regulatory submissions planned. However, shares have been pressured by reports that TrumpRx is set for a 'dramatic expansion,' raising drug-pricing risk. Risk: ongoing patent cliff, pricing/IRA pressures, and uncertain pipeline contribution beyond 2028 keep analysts cautious despite the 6.8% dividend yield.
May 19Michael Burry discloses Pfizer stake amid Vyndamax patent settlements and reaffirmed 2026 guidanceMixed▶
Michael Burry's Scion disclosed a new Pfizer position, with the stock trading around $25.75 at a 6.66% dividend yield and ~9x forward P/E. PFE entered patent settlement agreements with Dexcel, Hikma, and Cipla extending the effective US patent expiry on Vyndamax to June 1, 2031, protecting a key franchise from generic entry. Q1 2026 revenue of $14.5B (up 5% YoY) beat estimates as new and acquired products offset declining Covid vaccine and Paxlovid sales, and the company reaffirmed full-year guidance of $2.80-3.00 adjusted EPS and $59.5-62.5B revenue. Oncology and weight-loss pipeline progress and 22% operational growth on new launches underpinned the print. Risk: Paxlovid/Covid vaccine revenue is expected to decline another ~$1.5B to roughly $5B, and longer-term revenue base remains in transition.
May 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 15Pfizer reaffirms 2026 guidance after Q1 beat; pipeline advances with VEPPANU FDA approval and ELREXFIO Phase 3 results offset Covid revenue declinesPositive▶
Pfizer reported Q1 2026 revenue of $14.45B (up from $13.72B YoY) and adjusted EPS of $0.75, beating estimates. Management reaffirmed 2026 guidance: $59.5B-$62.5B revenue and $2.80-$3.00 adjusted EPS. Recently launched and acquired products grew 22% YoY operationally, offsetting expected $1.5B drop in Covid product revenue (to $5B) and a similar $1.5B headwind from loss-of-exclusivity drugs. Pipeline wins include FDA approval of VEPPANU, positive Phase 3 ELREXFIO results, and VYNDAMAX patent extension to 2031. Board declared a $0.43 Q2 dividend payable June 12. Pfizer is leveraging the $10B Metsera obesity acquisition for long-term growth. Stock trades at ~9.1x forward earnings with a 6.7% dividend yield. Risk: declining Covid revenue and patent cliffs continue to pressure top line.
May 14Pfizer reaffirmed 2026 guidance ($2.80-$3.00 adjusted EPS, $59.5B-$62.5B revenue) after Q1 revenue of $14.5B; Goldman Sachs reset its forecast on May 12 amid LOE concerns.Neutral▶
Pfizer reaffirmed its full-year 2026 outlook of $2.80-$3.00 adjusted EPS and $59.5-$62.5B revenue after Q1 revenue of $14.5B (+2% operational), with the core business excluding COVID products growing 7% operationally. The 'launched and acquired' portfolio delivered 22% operational revenue growth, anchored by Padcev (oncology), Nurtec ODT (migraine), and Abrysvo (RSV). The board declared a $0.43 Q2 dividend (350th consecutive quarterly dividend). Pipeline progress includes FDA approval of VEPPANU, positive Phase 3 results for ELREXFIO, and VYNDAMAX patent extension through 2031. Goldman Sachs reset its Pfizer forecast on May 12, with analysts framing PFE as a 'classic hold' trading near $26.58 with a consensus PT of $29.29 (~10% upside) plus a 6.7% dividend yield. Risk: loss-of-exclusivity wave for older drugs over the next few years will weigh on top line; LOE remains the dominant overhang.
May 13Pfizer Q1 2026 beat estimates and reaffirmed full-year guidance of $2.80-$3.00 adjusted EPS on $59.5B-$62.5B revenue, with oncology pipeline wins offsetting Covid product declines.Mixed▶
Pfizer posted Q1 2026 earnings and revenue that topped estimates as recently launched and acquired products showed growth, offsetting declining Covid vaccine and Paxlovid revenue. The company reaffirmed 2026 outlook with adjusted EPS of $2.80-$3.00 and revenue of $59.5B-$62.5B. Pipeline advances include FDA approval of VEPPANU, positive Phase 3 results for ELREXFIO, and VYNDAMAX patent extension to 2031. Goldman Sachs lowered its price target while maintaining a Hold rating. Consensus among 30 analysts is Buy. Loss of exclusivity and oncology competition remain key risks.
May 12Pfizer Q1 2026 beat estimates with $14.45B revenue and reaffirmed full-year guidance of $59.5-$62.5B as 22% growth in launched/acquired products offset COVID drug declines.Positive▶
Pfizer reported Q1 2026 EPS of $0.75 (ex-items) and revenue of $14.45B versus $13.72B a year ago, topping estimates. The company reaffirmed full-year 2026 adjusted EPS guidance of $2.80-$3.00 and revenue of $59.5B-$62.5B. Launched and acquired products grew 22% operationally, with Padcev up 39% and oncology biosimilars up 52%, helping offset an expected $1.5B decline in Covid product sales. Pfizer also extended VYNDAMAX patent protection through 2031 and is pursuing a $10B acquisition of obesity biotech Metsera. Risk: continued exclusivity losses are expected to drive another $1.5B revenue headwind in 2026. Goldman Sachs reset its Pfizer price forecast around the same period.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| LLYELI | $1,099.89 | -1.09% | +1.9% | 27.3x | 0.51 | $1.08T |
| JNJJOHNSON | $228.45 | -2.46% | +3.6% | 20.7x | 0.23 | $633.2B |
| MRKMERCK | $114.08 | -1.18% | +3.3% | 13.5x | 0.20 | $320.0B |
| PFEPFIZER | $25.28 | -2.49% | +1.8% | 8.6x | 0.31 | $138.6B |
| BMYBRISTOL | $54.15 | -2.05% | +3.0% | 9.4x | 0.23 | $118.7B |
| ZTSZOETIS | $78.71 | +1.88% | +3.2% | 10.1x | 0.75 | $31.4B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.